Tag: capital

Vero Beach, Fla., July 09, 2025 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (the “Company”) (NYSE: ORC) announced today that the Board of Directors of the Company declared a monthly cash dividend for the month of July 2025. The dividend of $0.12 per share will be paid August 28, 2025 to holders of record of the Company’s common stock on July 31, 2025, with an ex-dividend date of July 31, 2025. The Company plans on announcing its next common stock dividend on August 13, 2025.

MIDLAND, Texas, July 09, 2025 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) announced today that its operating company, Viper Energy Partners LLC (the “Operating Company”) has priced an offering (the “Notes Offering”) of $500,000,000 in aggregate principal amount of 4.900% senior notes that will mature on August 1, 2030 (the “2030 Notes”) and $1,100,000,000 in aggregate principal amount of 5.700% senior notes that will mature on August 1, 2035 (the “2035 Notes”, together with the 2030 Notes, the “Notes”). The price to the public was 99.902% of the principal amount for the 2030 Notes and 99.636% of the principal amount for the 2035 Notes.

HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- APA Corporation (Nasdaq: APA) today provided supplemental information regarding certain second-quarter 2025 financial and operational results. This information is intended only to provide additional information regarding current estimates management believes will affect results for the second-quarter 2025. It is provided to assist investors, analysts and others in formulating their own estimates, and is not intended to be a comprehensive presentation of all factors that will affect second-quarter 2025 results. Actual results and the impact of factors identified here may vary depending on the impact of other factors not identified here and are subject to finalization of the financial reporting process for second-quarter 2025.

Talent concentrates in global tech hubs as AI reshapes workforce demand and location strategy

Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development (“R&D”) and Chief Medical Officer (“CMO”) and Martine Zimmermann, PharmD, as Executive Vice President (“EVP”) of Regulatory Affairs and Quality Assurance.